AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A kit for the combined use for the treatment of cancer patients, which set comprises the following components:

a) an antigen comprising at least one epitope of a cellular surface protein, or an antibody directed against~~:~~ the cellular surface protein, and

b) an antigen comprising at least one epitope of an aberrant protein glycosylation, or an antibody directed against the aberrant protein glycosylation.

2. **(Original)** A kit according to claim 1, characterized in that the components a) and b) are contained in one pharmaceutical preparation each or in a single pharmaceutical preparation suitable for immunotherapy.

3. **(Original)** A kit according to claim 2, characterized in that the pharmaceutical preparation is formulated as a vaccine.

4. **(Original)** A kit according to claim 2, characterized in that the pharmaceutical preparation is formulated as an intravenously tolerable product.

5. **(Currently Amended)** A kit according to ~~any one of~~ claims ~~1 to 4~~, characterized in that the antigen of component a) represents an epitope of a cellular adhesion protein, in particular of a protein selected from the group of EpCAM, NCAM and CEA.

6. **(Currently Amended)** A kit according to ~~any one of~~ claims ~~1 to 4~~, characterized in that the antigen of component a) is an epitope of a surface receptor, in particular a receptor molecule selected from the group of the EGF receptor family, CD55 receptor, transferrin receptor and P-glycoprotein.

7. **(Currently Amended)** A kit according to ~~any one of~~ claims ~~1 to 6~~, characterized in that the antigen of component b) represents an epitope of a carbohydrate selected from the group of Lewis antigens, in particular Lewis y and/or Lewis b, sialyl-Tn and Globe H.

8. **(Currently Amended)** A kit according to ~~any one of~~ claims ~~1 to 7~~, characterized in that the antigen of component a) represents an epitope of the EpCAM molecule or of the Her-2/neu receptor, and the antigen of component b) represents an epitope of the Lewis Y molecule_

9. **(Currently Amended)** ~~The use of a kit according to claim 1 for preparing a diagnostic agent~~ A method for the immunologic determination of tumor cells of a solid tumor or disseminated tumor cells of a~~n~~ cancer disease which comprises

a) exposing a sample from a cancer patient to:

(i) an antigen comprising at least one epitope of a cellular surface protein, or an antibody directed against the cellular surface protein, and

(ii) an antigen comprising at least one epitope of an aberrant protein glycosylation, or an antibody directed against the aberrant protein glycosylation; and

b) determining the immunological response.

10. **(Currently Amended)** The ~~use~~ method according to claim 9, ~~characterized in that~~ wherein the determination is carried out within the scope of the treatment of cancer patients.

11. **(Currently Amended)** The ~~use~~ method according to claim 9, ~~characterized in that~~ wherein said sample comprise tumor cells from samples of peripheral blood or bone marrow ~~are determined~~.

12. **(Currently Amended)** The ~~use~~ method according to claim 9 or 10, ~~characterized in that~~ wherein an antibody titer against the antigens of the components is determined.

13. **(Currently Amended)** The ~~use~~ method according to claim 12, ~~characterized in that~~ wherein the determination is carried out for monitoring a treatment of a cancer patient.

14. **(Currently Amended)** A method for immunologic selection of a tumor-specific target antigen or of antibodies directed against the target antigen by ~~using a kit according to claim 1, characterized in that~~ exposing a sample from a cancer patient to

(a) an antigen comprising at least one epitope of a cellular surface protein, or an antibody directed against the cellular surface protein, and

(b) an antigen comprising at least one epitope of an aberrant protein glycosylation, or an antibody directed against the aberrant protein glycosylation; wherein

the antigen is a neoepitope which is formed by the glycosylatien of an antigen of component a) with an antigen of component b).

15. **(Currently Amended)** ~~A preparation of an~~ An antigen composition which comprises a neoepitope or its mimic, ~~obtainable~~ prepared by ~~a~~ the method according to claim 14.

16. **(Currently Amended)** A ~~preparation~~ composition according to claim 15 wherein the antigen is a naturally occurring antigen or a fragment thereof.

17. **(Currently Amended)** A method according to claim 14, ~~characterized in that~~ wherein an antibody directed against the neoepitope is selected and prepared by using a kit according to claim 1.

18. **(Currently Amended)** ~~Preparation of an~~ An antibody composition with specificity for a neo-epitope, ~~obtainable~~ prepared by ~~a~~ the method according to claim 17.

19. **(Original)** A diagnostic agent based on a kit according to claim 1, characterized in that it contains a reagent for determining an immune reaction with components a) and b), or with antibodies against these.

20. **(Currently Amended)** An agent according to claim 19, ~~characterized in that~~ wherein the reagent is labelled with a fluorescent agent, a chromogen, a radiolabel or an enzyme.

21. **(Currently Amended)** An agent according to claim 20, ~~characterized in that~~ wherein the reagent is immobilized on a carrier.

22. **(Currently Amended)** An agent according to claim 21, ~~characterized in that~~ wherein the carrier is a matrix for immunoaffinity chromatography.